Fig. 7.

CD103 + DCs are critical for effective anti-tumor responses to RT combined with anti-TIGIT therapy. a. Frequency of CD103 + DCs among total myeloid cells infiltrating MC38, B16-F10, and LLC tumor models. Myeloid cells were gated on CD11b + and/or CD11c + cells within CD45 + cells. b. Quantification of CD155 on CD103 + DCs purified from MC38 TdLNs, non-draining LNs, and healthy mouse LNs on day 10 following tumor challenge. The gating strategy is shown in Fig. S9. c. MC38 tumor-bearing WT or BATF3^−/− mice were treated with RT plus anti-TIGIT therapy or RT alone on day 10 after the tumor challenge. Data are shown as mean ± SEMs (standard errors of the mean) for two independent experiments (n = 4–5). (d-e). The production of IFN-γ (interferon gamma) and TNF-α (tumor necrosis factor alpha) by CD8 + T-cells in tumor tissues d and TdLNs e was analyzed herein. f. WT and BATF3.^−/− mice were inoculated with MC38 cells and treated with RT and anti-TIGIT therapy as described in Fig. 3a. Moreover, 200 μg of anti-CD8 monoclonal antibodies (mAb) was administered as described in Fig. 5a. Tumor growth was monitored after RT. Data are shown as means ± SEM (standard errors of the mean) of two independent experiments (n = 5). *p < 0.05; ***p < 0.001; ****p < 0.0001. BATF3, basic leucine zipper transcription factor ATF-like 3; DCs, dendritic cells; LNs, lymph nodes; mAb, monoclonal antibodies; NS, not statistically significant; RT, radiotherapy; TdLNs, tumor draining lymph nodes; TIGIT, T cell immunoreceptor with immunoglobulin and ITIM (immunoreceptor tyrosine-based inhibitory motif) domains; WT, wild type